Menu Search
Equities

Tissue Regenix Group PLC

LSW:FRA

Tissue Regenix Group PLC

Actions
  • Price (EUR)0.705
  • Today's Change0.000 / 0.00%
  • Shares traded400.00
  • 1 Year change+14.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.

  • Revenue in GBP (TTM)25.03m
  • Net income in GBP-866.73k
  • Incorporated2006
  • Employees76.00
  • Location
    Tissue Regenix Group PLCUnit 3Phoenix Court, Lotherton Way, GarforthLEEDS LS25 2GYUnited KingdomGBR
  • Phone+44 190 456 7609
  • Fax+44 190 438 0517
  • Websitehttps://www.tissueregenix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.